Estimation of New Drug Product Approval Probabilities in Phased Clinical Trials

Okeh UM; Oyeka ICA

Authors

Okeh UM
Oyeka ICA

Keywords:

evaluation committees, product, volunteer, probabilities, phased controlled clinical trials, diagnostic screening tests

Abstract

Abstract not found

Downloads

How to Cite

Estimation of New Drug Product Approval Probabilities in Phased Clinical Trials. (2016). Global Journal of Medical Research, 16(F5), 5-16. https://medicalresearchjournal.org/index.php/GJMR/article/view/1210

Download Citation

References

K Rising, P Bacchetti, L Bero (2009) Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation.

Jvs Gobburu, L Lesko (2009) Quantitative Disease, Drug, and Trial Models. 49, 291-301.

S Chow, J Liu (2004) Design and Analysis of Clinical Trials: Concept and Methodologies.

T Huff (2003) The Rise of Early Modern Science: Islam, China, and the West.

I Lipkovich, D Adams, C Mallinckrodt, D Faries, D Baron, J Houston (2008) Evaluating Dose Response from flexible Dose Clinical Trials.

S Pocock (2004) Clinical Trials. A Practical Approach.

Val Gebski, Elaine Beller, Anthony Keech (2001) Randomised controlled trials: elements of a good study. 175(5), 272-274.

G Koren, M Boloja, D Long, Y Feldman, N Shear (1998) Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. 160, 1190-1194.

Ann Dally, Thalidomide (1998) Thalidomide: was the tragedy preventable?. 351(9110), 1197-1199.

G Koren, A Pastuszak (1990) Prevention of unnecessary pregnancy termination by counselling women on drug, chemical and radiation exposure during the first trimester. 41, 657-661.

Gideon Koren, Anne Pastuszak, Shinya Ito (1998) Drugs in Pregnancy. 338(16), 1128-1137.

R Collier (2009) Drug development cost estimates hard to swallow. 3(3), 279-280.